A1 - STAFF A1 - PUBLICATIONS A1 - RESEARCH
          
 
 
 
  2016  
     
 
  • Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami. Obser T, Ledford-Kraemer M, Oyen F, Brehm MA, Denis CV, Marschalek R, Montgomery RR, Sadler JE, Schneppenheim S, Budde U, Schneppenheim R. J Thromb Haemost. 2016 Jun 25. doi: 10.1111/jth.13398. [Epub ahead of print)

  • Mutual A domain interactions in the force sensing protein von Willebrand factor. Posch S, Aponte-Santamaría C, Schwarzl R, Karner A, Radtke M, Gräter F, Obser T, König G, Brehm MA, Gruber HJ, Netz RR, Baldauf C, Schneppenheim R, Tampé R, Hinterdorfer P.J Struct Biol. 2016 Apr 23. pii: S1047-8477(16)30081-8. doi: 10.1016/j.jsb.2016.04.012. (Epub ahead of print)

  • Force sensing by the vascular protein von Willebrand factor is tuned by a strong intermonomer interaction. Müller JP, Mielke S, Löf A, Obser T, Beer C, Bruetzel LK, Pippig DA, Vanderlinden W, Lipfert J, Schneppenheim R, Benoit M. Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1208-13. doi: 10.1073/pnas.1516214113. Epub 2016 Jan 19.

  • Jochen P. MüllerAchim LöfSalomé MielkeTobias ObserLinda K. BruetzelWillem VanderlindenJan LipfertReinhard Schneppenheim, and Martin Benoit, "pH-Dependent Interactions in Dimers Govern the Mechanics and Structure of von Willebrand Factor" Biophysical Journal, 111(2), 312-322

  • Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers. Lippok S, Radtke M, Obser T, Kleemeier L, Schneppenheim R, Budde U, Netz RR, Rädler JO. Biophys J. 2016 Feb 2;110(3):545-54. doi: 10.1016/j.bpj.2015.12.023.

 
   
 
 
  2015  
   
 
  • von Willebrand factor is dimerized by protein disulfide isomerase. Lippok S, Kolšek K, Löf A, Eggert D, Vanderlinden W, Müller JP, König G, Obser T, Röhrs K, Schneppenheim S, Budde U, Baldauf C, Aponte-Santamaría C, Gräter F, Schneppenheim R, Rädler JO, Brehm MA.Blood. 2016 Mar 3;127(9):1183-91. doi:10.1182/blood-2015-04-641902. Epub 2015 Dec 15.

  • Force-Sensitive Autoinhibition of the von Willebrand Factor Is Mediated by Interdomain Interactions Camilo Aponte-Santamaría, Volker Huck, Sandra Posch, Agnieszka K. Bronowska, Sandra Grässle, Maria A. Brehm, Tobias Obser, Reinhard Schneppenheim, Peter Hinterdorfer, Stefan W. Schneider, Carsten Baldauf, Frauke Gräter Biophys J. 2015 May 5; 108(9): 2312–2321. doi: 10.1016/j.bpj.2015.03.041

 
   
 
 
  2014  
     
 
  • Emma Kraus, Kristina Kraus, Tobias Obser, Florian Qyen, Ulrike Klemm, Reinhard Schneppenheim, Maria A. Brehm - Platelet-free shear flow assay facilitates analysis of shear-dependent functions of VWF and ADAMTS13 (Audioslides: KLICK HERE / Abstract: KLICK HERE) Thrombosis Research 2014 August 28 [Epub ahead of print]

  • Hassenpflug WA, Budde U, Schneppenheim S, Schneppenheim R. Inherited Thrombotic Thrombocytopenic Purpura in Children. Semin Thromb Hemost. 2014 May 11. [Epub ahead of print]

  • Grässle S, Huck V, Pappelbaum KI, Gorzelanny C, Aponte-Santamaría C, Baldauf C, Gräter F, Schneppenheim R, Obser T, Schneider SW. von Willebrand Factor Directly Interacts With DNA From Neutrophil Extracellular Traps. Arterioscler Thromb Vasc Biol. 2014 May 1. [Epub ahead of print]

  • Brehm MA, Huck V, Aponte-Santamaría C, Obser T, Grässle S, Oyen F, Budde U, Schneppenheim S, Baldauf C, Gräter F, Schneider SW, Schneppenheim R. VWD type 2A phenotypes IIC, IID and IIE: A day in the life of shear stressed mutant VWF. Thromb. Haemost. 2014;112:E-pub ahead of print.

 
     
 
 
 

2013

 
        
 
  • Hasselblatt M, Isken S, Linge A, Eikmeier K, Jeibmann A, Oyen F, Nagel I, Richter J, Bartelheim K, Kordes U, Schneppenheim R, Frühwald M, Siebert R, Paulus W, High-resolution genomicanalysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors, Genes Chromosomes Cancer. 2013 Feb;52(2):185-90.

  • Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A., VWF propeptide and ratios between VWF, VWF propeptide and FVIII in the characterization of type 1 von Willebrand disease, Blood. 2013 Jan 24. [Epub ahead of print]

  • Ahmad F, Jan R, Kannan M, Obser T, Hassan MI, Oyen F, Budde U, Saxena R, Schneppenheim R, Characterisation of mutations and molecular studies of type 2 von Willebrand disease”, Thromb Haemost. 2013 Jan 8;109(1):39-46.

  • Pappelbaum KI, Gorzelanny C, Grassle S, Suckau J, Laschke MW, Bischoff M, Bauer C, Schorpp-Kistner M, Weidenmaier C, Schneppenheim R, Obser T, Sinha B, Schneider SW. Ultralarge von willebrand factor fibers mediate luminal staphylococcus aureus adhesion to an intact endothelial cell layer under shear stress. Circulation. 2013;128:50-59.

  • Lippok S, Obser T, Müller JP, Stierle VK, Benoit M, Budde U, Schneppenheim R, Rädler JO. Exponential size distribution of von Willebrand factor. Biophys J. 2013 Sep 3;105(5):1208-16. doi: 10.1016/j.bpj.2013.07.037.

  • Langer F, Obser T, Oyen F, Spath B, Holstein K, Greinacher A, White JG, Budde U, Bokemeyer C, Schneppenheim R. Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion. Thromb Haemost. 2013 Dec 2;111(4).

  • Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013 Mar 21;121(12):2336-9.

  • Ahmad F, Budde U, Jan R, Oyen F, Kannan M, Saxena R, Schneppenheim R. Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients. Thromb Haemost. 2013 Apr;109(4):652-60.

  • Fuchs B, de Witt S, Solecka BA, Kröning M, Obser T, Cosemans JM, Schneppenheim R, Heemskerk JW, Kannicht C. Distinct role of von Willebrand factor triplet bands in glycoprotein Ib-dependent platelet adhesion and thrombus formation under flow. Semin Thromb Hemost. 2013 Apr;39(3):306-14.

  • Jokela V, Lassila R, Szanto T, Joutsi-Korhonen L, Armstrong E, Oyen F, Schneppenheim S, Schneppenheim R., Phenotypic and genotypic characterization of 10 Finnish patients with von Willebrand disease type 3: discovery of two main mutations. Haemophilia. 2013 Nov;19(6):e344-8. doi: 10.1111/hae.12225. Epub 2013 Jul 9.

 
        
 
 
 

2012

 
        
 
  • Lehmberg K, Grosse R, Muckenthaler MU, Altamura S, Nielsen P, Schmid H, Graubner U, Oyen F, Zeller W, Schneppenheim R, Janka GE,  Administration of recombinant erythropoietin alone does not improve the phenotype in iron refractory iron deficiency anemia patients, Ann Hematol. 2012 Nov 20.

  • Castaman G, Giacomelli SH, Jacobi PM, Obser T, Budde U, Rodeghiero F, Schneppenheim R, Haberichter SL, “Reduced von Willebrand factor secretion is associated with loss of Weibel-Palade body formation”,  J Thromb Haemost. 2012 May;10(5):951-8.

 
        
 
 
  

2011

 
        
 
  • Schneppenheim R., The pathophysiology of von Willebrand disease: therapeutic implications, Thromb Res. 2011;128 Suppl 1:S3-7.

  • Schneppenheim R, Budde U, “Von Willebrand factor and ADAMTS13 balancing primary haemostasis”, Hamostaseologie. 2011 Nov;31(4):275-80. 

  • Schneppenheim R, Budde U, von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein, J      Thromb Haemost. 2011 Jul;9 Suppl 1:209-15. 

  • Hasselblatt M, Gesk S, Oyen F, Rossi S, Viscardi E, Giangaspero F, Giannini C, Judkins AR, Frühwald MC, Obser T, Schneppenheim R, Siebert R, Paulus W, Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression, Am J Surg Pathol. 2011 Jun;35(6):933-5.

  • Mohl A, Boda Z, Jager R, Losonczy H, Marosi A, Masszi T, Nagy E, Nemes L, Obser T, Oyen F, Radványi G, Schlammadinger Á, Szélessy ZS, Várkonyi A, Vezendy K, Vilimi B, Schneppenheim R, Bodó I, “Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population”,  J Thromb Haemost. 2011 May;9(5):945-52. 

  • Roth L, Marschalek R, Oldenburg J, Oyen F, Schneppenheim R, Characterisation of two novel large F8 deletions in patients with severe haemophilia A and factor VIII inhibitors, Thromb Haemost. 2011 Feb;105(2):279-84.

  • Kordes U, Schneppenheim R, Briem-Richter A, Scherpe S, Schäfer HJ, Parvovirus B19 infection and autoimmune hepatitis in a child with sickle cell anemia, Pediatr Blood Cancer. 2011 Feb;56(2):323-4.

  • Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake I, “A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease”, Haemophilia. 2011 Jan;17(1):165-6.

 
  
         
A1 - STAFF A1 - PUBLICATIONS A1 - RESEARCH